ClinicalTrials.gg
CompletedNCT04096326Updated Jul 28, 2023Results posted

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Phase 2 interventional study of AGN-151586 and Placebo in Glabellar Lines, sponsored by Allergan. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

02

Conditions studied

  • Glabellar Lines
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).

Exclusion criteria

Exclusion Criteria:

  • Known immunization or to any botulinum neurotoxin serotype
  • Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator
  • Any brow or eyelid ptosis, as determined by the investigator
  • Infection or skin disorder at the injection sites
  • History of facial nerve palsy
  • Any uncontrolled systemic disease
  • Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)
  • Anticipated need for surgery or overnight hospitalization during the study
  • Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery)
  • Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation
  • Current enrollment in an drug or device study or participation in such a study within 30 days of Screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
198 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1: Placebo

    Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.

    Drug: Placebo

  • Experimental
    Cohort 1: AGN-151586

    Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.

    Drug: AGN-151586

  • Placebo comparator
    Cohort 2: Placebo

    Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.

    Drug: Placebo

  • Experimental
    Cohort 2: AGN-151586

    Participants received AGN-151586, IM injections in the glabellar complex on Day 1.

    Drug: AGN-151586

  • Placebo comparator
    Cohort 3: Placebo

    Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.

    Drug: Placebo

  • Experimental
    Cohort 3: AGN-151586

    Participants received AGN-151586, IM injections in the glabellar complex on Day 1.

    Drug: AGN-151586

  • Placebo comparator
    Cohort 4: Placebo

    Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.

    Drug: Placebo

  • Experimental
    Cohort 4: AGN-151586

    Participants received AGN-151586, IM injections in the glabellar complex on Day 1.

    Drug: AGN-151586

  • Placebo comparator
    Cohort 5: Placebo

    Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.

    Drug: Placebo

  • Experimental
    Cohort 5: AGN-151586

    Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.

    Drug: AGN-151586

Interventions

  • AGN-151586 solution for injection.

  • DrugPlacebo

    Placebo solution for injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7

    Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline (Day 1) through Day 7

  2. Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.

    Time frame: From first dose of study drug until the end of study (up to 42 days)

  3. Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention

    Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.

    Time frame: From first dose of study drug until the end of study (up to 42 days)

  4. Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention

    Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.

    Time frame: From first dose of study drug until the end of study (up to 42 days)

  5. Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention

    Potentially clinically significant post intervention values in 12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semi-supine or supine position as defined in the SAP. A post-baseline value is considered potentially clinically significant if it meets either the observed-value or the change-from-baseline criteria such as QRS interval observed value: ≥ 150 msec; PR interval observed value: ≥ 250 msec; QTcB observed value: \> 500 msec or change from baseline value: increase of \> 60 msec; QTcF observed value: \> 500 msec or change from baseline value: increase of \> 60 msec.

    Time frame: From first dose of study drug until the end of study (up to 42 days)

  6. Number of Participants With Anti-drug Antibodies (ADAs)

    Number of participants with positive anti-drug antibodies are reported. Binding and neutralizing anti-bodies are evaluated as anti-drug antibodies. Only participants with positive samples for binding antibodies have been analyzed for presence of neutralizing antibodies.

    Time frame: Up to Day 42

07

Results

Posted Jul 28, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Started832122811271030931
Completed83112281022930931
Not completed0100151000
Withdrew: Withdrawal by subject0000001000
Withdrew: Lost to follow-up0100000000
Withdrew: Covid-19-related reasons0000150000

Outcome measures

PrimaryPercentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7

Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline (Day 1) through Day 7
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7
percentage of participantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 70.0 (NA to NA)40.6 (23.7 to 59.4)0.0 (NA to NA)46.4 (27.5 to 66.1)18.2 (2.3 to 51.8)70.4 (49.8 to 86.2)20.0 (2.5 to 55.6)83.3 (65.3 to 94.4)11.1 (0.3 to 48.2)96.8 (83.3 to 99.9)
Statistical analysis
  • Cohort 1: Placebo vs Cohort 1: AGN-151586 · Cochran-Mantel-Haenszel · p = 0.0096 (P-value was based on Cochran-Mantel-Haenszel (CMH) tests stratified by baseline GL severity at maximum frown to compare each AGN-151586 study intervention group versus placebo for each cohort.) · Rate difference: 40.6 · 95% CI 23.6 to 57.6
  • Cohort 2: Placebo vs Cohort 2: AGN-151586 · Cochran-Mantel-Haenszel · p = 0.0094 (P-value was based on CMH tests stratified by baseline GL severity at maximum frown to compare each AGN-151586 study intervention group versus placebo for each cohort.) · Rate difference: 46.4 · 95% CI 28.0 to 64.9
  • Cohort 3: Placebo vs Cohort 3: AGN-151586 · Cochran-Mantel-Haenszel · p = 0.0044 (P-value was based on CMH tests stratified by baseline GL severity at maximum frown to compare each AGN-151586 study intervention group versus placebo for each cohort.) · Rate difference: 52.2 · 95% CI 23.6 to 80.8
  • Cohort 4: Placebo vs Cohort 4: AGN-151586 · Cochran-Mantel-Haenszel · p = 0.0026 (P-value was based on CMH tests stratified by baseline GL severity at maximum frown to compare each AGN-151586 study intervention group versus placebo for each cohort.) · Rate difference: 63.3 · 95% CI 35.2 to 91.5
  • Cohort 5: Placebo vs Cohort 5: AGN-151586 · Cochran-Mantel-Haenszel · p = 0.0000 (P-value was based on CMH tests stratified by baseline GL severity at maximum frown to compare each AGN-151586 study intervention group versus placebo for each cohort.) · Rate difference: 85.7 · 95% CI 64.2 to 100.0
PrimaryNumber of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.

Time frame:
From first dose of study drug until the end of study (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)3157107939112
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention

Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.

Time frame:
From first dose of study drug until the end of study (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention
ParticipantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention0715340458
PrimaryNumber of Participants With Potentially Clinically Significant Vital Signs Post Intervention

Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.

Time frame:
From first dose of study drug until the end of study (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention
ParticipantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention2002100101
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention

Potentially clinically significant post intervention values in 12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semi-supine or supine position as defined in the SAP. A post-baseline value is considered potentially clinically significant if it meets either the observed-value or the change-from-baseline criteria such as QRS interval observed value: ≥ 150 msec; PR interval observed value: ≥ 250 msec; QTcB observed value: \> 500 msec or change from baseline value: increase of \> 60 msec; QTcF observed value: \> 500 msec or change from baseline value: increase of \> 60 msec.

Time frame:
From first dose of study drug until the end of study (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention
ParticipantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention0000000000
PrimaryNumber of Participants With Anti-drug Antibodies (ADAs)

Number of participants with positive anti-drug antibodies are reported. Binding and neutralizing anti-bodies are evaluated as anti-drug antibodies. Only participants with positive samples for binding antibodies have been analyzed for presence of neutralizing antibodies.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs)
ParticipantsCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
Binding Antibodies0000000001
Neutralizing Antibodies0000000000

Adverse events

Collected over All-cause mortality was reported from enrollment to the end of study; median time on follow-up was 42 days for the placebo and AGN-151586 arms, respectively. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 42 days after the last dose of study drug.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Placebo0/8 (0%)0/8 (0%)3/8 (37.5%)
Cohort 1: AGN-1515860/32 (0%)0/32 (0%)15/32 (46.9%)
Cohort 2: Placebo0/12 (0%)0/12 (0%)7/12 (58.3%)
Cohort 2: AGN-1515860/28 (0%)0/28 (0%)10/28 (35.7%)
Cohort 3: Placebo0/11 (0%)0/11 (0%)7/11 (63.6%)
Cohort 3: AGN-1515860/27 (0%)0/27 (0%)9/27 (33.3%)
Cohort 4: Placebo0/10 (0%)0/10 (0%)3/10 (30%)
Cohort 4: AGN-1515860/30 (0%)0/30 (0%)9/30 (30%)
Cohort 5: Placebo0/9 (0%)0/9 (0%)1/9 (11.1%)
Cohort 5: AGN-1515860/31 (0%)0/31 (0%)12/31 (38.7%)
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586
HeadacheNervous system disorders0/82/322/124/282/111/273/102/300/92/31
Injection site painGeneral disorders0/86/323/121/281/117/272/104/300/96/31
EczemaSkin and subcutaneous tissue disorders0/80/322/120/280/110/270/100/300/90/31
NasopharyngitisInfections and infestations1/81/320/120/280/110/270/100/300/90/31
InfluenzaInfections and infestations1/80/320/120/280/110/270/100/300/90/31
Breast indurationReproductive system and breast disorders1/80/320/120/280/110/270/100/300/90/31
Injection site pruritusGeneral disorders0/80/320/120/280/110/270/100/301/90/31
DiarrhoeaGastrointestinal disorders0/80/320/120/280/110/271/100/300/90/31
PyrexiaGeneral disorders0/80/320/120/281/110/270/100/300/90/31
DizzinessNervous system disorders0/80/321/120/281/111/270/100/300/90/31

Baseline characteristics

Modified intent-to-treat (mITT) population included all randomized participants who received the study intervention and who had at least one postintervention investigator-rated facial wrinkle scale with photonumeric guide (FWS) measurement at maximum frown.

Age, Continuous
Age, Continuous(years)Cohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586Total
Mean49.9 ± 6.2452.8 ± 8.8547.0 ± 9.3950.9 ± 10.1050.1 ± 10.6347.5 ± 10.5339.0 ± 7.9445.3 ± 8.0651.1 ± 11.3746.4 ± 10.3048.3 ± 9.91
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586Total
Female72912251124926930182
Male130303140116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586Total
Hispanic or Latino2934483120752
Not Hispanic or Latino623924719718924146
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: PlaceboCohort 1: AGN-151586Cohort 2: PlaceboCohort 2: AGN-151586Cohort 3: PlaceboCohort 3: AGN-151586Cohort 4: PlaceboCohort 4: AGN-151586Cohort 5: PlaceboCohort 5: AGN-151586Total
American Indian or Alaska Native00000000000
Asian03110100006
Native Hawaiian or Other Pacific Islander00010000124
Black or African American120200021210
White727102410261028726175
More than one race00101000002
Unknown or Not Reported00000000011
08

Study locations

9 sites
  • Center for Dermatology Clinical Research /ID# 237798
    Fremont, California 94538, United States
  • Ava T. Shamban MD - Santa Monica. /ID# 235353
    Santa Monica, California 90404-2208, United States
  • Skin and Cancer Associates, LLP /ID# 236231
    Miami, Florida 33137-3254, United States
  • Laser and Skin Surgery Center of Indiana /ID# 236588
    Indianapolis, Indiana 46260-2386, United States
  • Wilmington Dermatology Center /ID# 237055
    Wilmington, North Carolina 28403, United States
  • Kgl, Llc /Id# 234798
    Newtown Square, Pennsylvania 19073-2228, United States
  • DermResearch Inc. /ID# 234483
    Austin, Texas 78759, United States
  • Austin Institute for Clinical Research at SBA Dermatology /ID# 236646
    Houston, Texas 77056-4129, United States
  • Austin Institute for Clinical Research /ID# 237135
    Pflugerville, Texas 78660, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2020, 11 months.

Results were first posted in Jul 2023, 2 years 10 months after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 19, 2019
StartActual
Sep 26, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 9, 2020
Results delay requested
Jul 12, 2021
Results first posted
Jul 28, 2023
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04096326
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 19, 2019
Start date
Sep 26, 2019
Primary completion
Sep 9, 2020
Completion
Sep 9, 2020
Results posted
Jul 28, 2023
Last update
Jul 28, 2023

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: trenibotulinumtoxinE

Start the discussion